Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes

International Journal of Pharmaceutics

Volumn 374, Issue 1-2, 2009, Pages 145-152

  Gao, Jie ^a,b   Zhong, Wei ^a   He, Jinqiu ^a   Li, Huimei ^a   Zhang, He ^a   Zhou, Guichen ^a   Li, Bohua ^a,b   Lu, Ying ^a   Zou, Hao ^a   Kou, Geng ^a,b   Zhang, Dapeng ^a,b   Wang, Hao ^a,b   Guo, Yajun ^a,b   Zhong, Yanqiang ^a  

^a School of Pharmacy Second Military Medical University Guohe Road 325   (China)

^b National Engineering Research Center for Antibody Medicine   (China)

Author keywords

Breast cancer; Cytotoxicity; PE38KDEL; PEGylated immunoliposomes; RhuMAbHER2

Indexed keywords

AMINE; ANTIBODY CONJUGATE; CHOLESTEROL; DISTEAROYLPHOSPHATIDYLETHANOLAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; MACROGOL 2000; MALEIMIDE DERIVATIVE; MALEIMIDOPHENYLBUTYRATE; MONOCLONAL ANTIBODY; PHOSPHATIDYLCHOLINE; PYRIDYLTHIOPROPIONOYLAMINE; THIOL GROUP; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DERIVATIZATION; DRUG DELIVERY SYSTEM; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTERNALIZATION; NANOENCAPSULATION; PRIORITY JOURNAL; ZETA POTENTIAL;

ADP RIBOSE TRANSFERASES; BACTERIAL TOXINS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; EXOTOXINS; FEMALE; FLOW CYTOMETRY; HALF-LIFE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LIPOSOMES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RECEPTOR, ERBB-2; SULFHYDRYL COMPOUNDS; VIRULENCE FACTORS;

EID: 67349150699     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.03.018     Document Type: Article

References (23)

1. Allen T.M., Brandeis E., Hansen C.B., Kao G.Y., and Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta 1237 (1995) 99-108
2. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 (2004) 1818-1822
3. Chen H., Gao J., Lu Y., Kou G., Zhang H., Fan L., Sun Z., Guo Y., and Zhong Y. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J. Control. Release 128 (2008) 209-216
4. Erjavec V., Pavlica Z., Sentjurc M., and Petelin M. In vivo study of liposomes as drug carriers to oral mucosa using EPR oximetry. Int. J. Pharm. 307 (2006) 1-8
5. Gao J., Kou G., Wang H., Chen H., Li B., Lu Y., Zhang D., Wang S., Hou S., Qian W., Dai J., Zhao J., Zhong Y., and Guo Y. PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity. Breast Cancer Res. Treat. (2008) 10.1007/s10549-008-0043-0
6. Ito A., Kuga Y., Honda H., Kikkawa H., Horiuchi A., Watanabe Y., and Kobayashi T. Magnetic nanoparticle-loaded anti-immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Lett. 212 (2004) 167-175
7. Kocbek P., Obermajer N., Cegnar M., Kos J., and Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J. Control. Release 120 (2007) 18-26
8. Lopes de Menezes D.E., Pilarski L.M., and Allen T.M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 58 (1998) 3320-3330
9. Lv W., Guo J., Li J., Huang L., and Ping Q. Distribution of liposomal breviscapine in brain following intravenous injection in rats. Int. J. Pharm. 306 (2005) 99-106
10. Martin F.J., Hubbell W.L., and Papahadjopoulos D. Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab′ fragments via disulfide bonds. Biochemistry 20 (1981) 4229-4238
11. Moghimi S.M., and Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42 (2003) 463-478
12. Moreira J.N., Gaspar R., and Allen T.M. Targeting stealth liposomes in a mutine model of human small cell lung cancer. Biochim. Biophys. Acta 1515 (2001) 167-176
13. Park J.W., Benz C.C., and Martin F.J. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin. Oncol. 31 Suppl. 13 (2004) 196-205
14. Park T.G., Yong Lee., Sung H., and Nam Y. A new preparation method for protein loaded poly (d,l-lactic-coglycolic acid) microspheres and protein release mechanism study. J. Control. Release 55 (1998) 181-191
15. Pastan I., Hassan R., Fitzgerald D.J., and Kreitman R.J. Immunotoxin therapy of cancer. Nat. Rev. Cancer 6 (2006) 559-565
16. Pastan I., Hassan R., FitzGerald D.J., and Kreitman R.J. Immunotoxin treatment of cancer. Annu. Rev. Med. 58 (2007) 221-237
17. Sapra P., and Allen T.M. Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res. 42 (2003) 439-462
18. Shi N., Zhang Y., Zhu C., Boado R.J., and Pardridge W.M. Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 12754-12759
19. Song H., Zhang J., Han Z., Zhang X., Li Z., Zhang L., Fu M., Lin C., and Ma J. Pharmacokinetic and cytotoxic studies of PEGylated liposomal daunorubicin. Cancer Chemother. Pharmacol. 57 (2006) 591-598
20. Song S., Xue J., Fan K., Kou G., Zhou Q., Wang H., and Guo Y. Preparation and characterization of fusion protein truncated Pseudomonas exotoxin A (PE38KDEL) in Escherichia coli. Protein Expr. Purif. 44 (2005) 52-57
21. van Dam G.J., Bogitsh B.J., Fransen J.A., Kornelis D., van Zeyl R.J., and Deelder A.M. Application of the FITC-anti-FITC-gold system to ultrastructural localization of antigens. J. Histochem. Cytochem. 39 (1991) 1725-1728
22. Yang T., Cui F.D., Choi M.K., Cho J.W., Chung S.J., Shim C.K., and Kim D.D. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int. J. Pharm. 338 (2007) 317-326
23. Xu Z., Gu W., Huang J., Sui H., Zhou Z., Yang Y., Yan Z., and Li Y. In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int. J. Pharm. 288 (2005) 361-368